PT  - JOURNAL ARTICLE
AU  - de Oliveira Mendes-Aguiar, Carolina
AU  - do Monte Alves, Manoella
AU  - Lopes Machado, Amanda de Albuquerque
AU  - de Góis Monteiro, Glória Regina
AU  - Medeiros, Iara Marques
AU  - Queiroz, Jose Wilton
AU  - Lima, Iraci Duarte
AU  - Pearson, Richard D.
AU  - Wilson, Mary E.
AU  - Glesby, Marshall J.
AU  - do Nascimento, Eliana Lúcia Tomaz
AU  - Bezerra Jerônimo, Selma Maria
TI  - T-cell activation, senescence, and exhaustion in asymptomatic HIV/Leish<em>mania infantum</em> co-infection
AID  - 10.1101/2023.03.06.23286828
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.03.06.23286828
4099  - http://medrxiv.org/content/early/2023/03/06/2023.03.06.23286828.short
4100  - http://medrxiv.org/content/early/2023/03/06/2023.03.06.23286828.full
AB  - Background Leishmania infantum is an opportunistic parasitic infection. An immunocompromised state increases the risk of converting asymptomatic infection to symptomatic visceral leishmaniasis (VL), which has a ∼5% fatality rate even with treatment. HIV coinfection increases the risk of death from VL.Methods A cross-sectional study was performed between 2014 and 2016 to determine the prevalence of L. infantum infection in HIV positive subjects residing in the state of Rio Grande do Norte, Brazil (n=1,372) and of these a subgroup of subjects were followed longitudinally. Subsequent incident cases of VL were ascertained from a public health database through 2018. A subgroup (n=69) of the cross-sectional study subjects was chosen to assess immune status (T cell activation, senescence, exhaustion) and outcome. The data were compared between asymptomatic HIV+/L. infantum+ (HIV/Leish), symptomatic visceral leishmaniasis (VL), recovered VL, DTH+ (Delayed-Type Hypersensitivity response – Leishmanin skin test), AIDS/VL, HIV+ only (HIV+), and Non-HIV/Non L. infantum infection (control subjects).Results The cross-sectional study showed 24.2% of HIV+ subjects had positive anti-IgG Leishmania antibodies. After 3 years, 2.4% (8 of 333) of these HIV/Leish coinfected subjects developed AIDS/VL, whereas 1.05% (11 of 1,039) of HIV subjects with negative leishmania serology developed AIDS/VL. Poor adherence to antiretroviral therapy (p=0.0008) or prior opportunistic infections (p=0.0007) was associated with development of AIDS/VL. CD4+ (p=0.29) and CD8+ (p=0.38) T cells counts or viral load (p=0.34) were similar between asymptomatic HIV/Leish and HIV subjects. However, activated CD8+CD38+HLA-DR+ T cells were higher in asymptomatic HIV/Leish than HIV group. Likewise, senescent (CD57+) or exhausted (PD1+) CD8+ T cells were higher in asymptomatic HIV/Leish than in AIDS/VL or HIV groups.Conclusion Although asymptomatic HIV/Leish subjects had normal and similar CD4+ and CD8+ T cells counts, their CD8+T cells had increased activation, senescence, and exhaustion, which could contribute to risk of developing VL.Author Summary The frequency of asymptomatic HIV/Leishmania infantum (HIV/Leish) infection and the immunological status of subjects with HIV+ residing in the state of Rio Grande do Norte, Brazil, between 2014 and 2016 were studied. A high frequency of asymptomatic HIV/Leishmania infantum infection (HIV subjects with positive anti-IgG Leishmania antibodies) was found. Asymptomatic HIV/Leish subjects had CD8 T cells with higher markers of activation, senescence and exhaustion than the other groups (HIV-alone, symptomatic VL, Recovered VL, DTH+, AIDS/VL and Controls subjects). Poor adherence to antiretroviral therapy or history of previous opportunistic infection was associated with AIDS/VL. Asymptomatic HIV/Leish had high relative risk of developing AIDS/VL. Thus, subjects with HIV residing in endemic areas for VL should be assessed for their L. infantum infection status and advised to closely adhere to ART.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAFunding StatementTThe work was supported in part from a grant from the CNPq (universal 406076/2021-9) National Institutes of Health (NIH). Project number: AI 136032 National Institute of Science and Technology in Tropical Diseases (INCT-DT) – Ministério de Ciência, Tecnologia e Inovação, CNPq. Project Number: 465229/2014-0.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol was reviewed and approved by UFRN Human ethical review board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.